

Electronic Acknowledgement Receipt

EFS ID:	1315762
Application Number:	10531758
International Application Number:	
Confirmation Number:	5647
Title of Invention:	Substituted piperazines,(1,4) diazepines, and 2,5-diazabicyclo (2.2.1) heptanes as histamine h1 and/or h3 antagonists or histamine h3 reverse antagonists
First Named Inventor/Applicant Name:	Rachel Ancliff
Customer Number:	23347
Filer:	James P. Riek/Marjorie Pfeiffer
Filer Authorized By:	James P. Riek
Attorney Docket Number:	P33126USw
Receipt Date:	15-NOV-2006
Filing Date:	14-APR-2005
Time Stamp:	16:17:09
Application Type:	U.S. National Stage under 35 USC 371

Payment information:

Submitted with Payment	no
------------------------	----

File Listing:

Document Number	Document Description	File Name	File Size(Bytes)	Multi Part /.zip	Pages (if appl.)
1	Information Disclosure Statement (IDS) Filed	Supp_IDS.pdf	444094	no	3

Warnings:

Information:

This is not an USPTO supplied IDS fillable form

Total Files Size (in bytes):

444094

This Acknowledgement Receipt evidences receipt on the noted date by the USPTO of the indicated documents, characterized by the applicant, and including page counts, where applicable. It serves as evidence of receipt similar to a Post Card, as described in MPEP 503.

New Applications Under 35 U.S.C. 111

If a new application is being filed and the application includes the necessary components for a filing date (see 37 CFR 1.53(b)-(d) and MPEP 506), a Filing Receipt (37 CFR 1.54) will be issued in due course and the date shown on this Acknowledgement Receipt will establish the filing date of the application.

National Stage of an International Application under 35 U.S.C. 371

If a timely submission to enter the national stage of an international application is compliant with the conditions of 35 U.S.C. 371 and other applicable requirements a Form PCT/DO/EO/903 indicating acceptance of the application as a national stage submission under 35 U.S.C. 371 will be issued in addition to the Filing Receipt, in due course.